Here's Why GE HealthCare Technologies (GEHC) is a Strong Value Stock

GE HealthCare holds a Zacks Rank #2 (Buy), a Value Score of A and a VGM Score of B, supported by a 12.98x forward P/E. Six analysts raised their fiscal 2026 EPS estimates over the past 60 days, lifting the consensus by $0.04 to $4.93 per share; the company has averaged a 0.9% earnings surprise. The article presents GEHC as an attractive value candidate, although the information is analyst-rating based and is unlikely to materially move the stock on its own.

Analysis

This is not a high-conviction standalone catalyst: the estimate revision is modest and the source is promotional, so the relevant question is whether GEHC can convert a low-teens earnings multiple into a durable re-rating. The upside mechanism is operating leverage from service, software, and pharmaceutical-diagnostics mix: recurring and consumables-heavy revenue can support margins and reduce the cyclicality historically associated with large imaging-equipment orders. Over 6-18 months, evidence of mix improvement would differentiate GEHC from more procedure-volume-sensitive peers such as Philips (PHG) and justify a narrowing of its valuation discount to diversified medtech.

Near term (days to 1-3 months), incremental quant-screen and retail demand may be insufficient to move the shares materially absent an earnings catalyst. The more investable setup is a quarterly confirmation that orders, backlog conversion, and margins are improving simultaneously; a revenue beat driven only by equipment shipments without service attach-rate progress would not support multiple expansion. Key downside risks are hospital capital-budget delays, China imaging demand softness, FX, and pricing pressure from Siemens Healthineers (SHL.DE) and Canon; thesis is falsified by a guidance cut, deteriorating orders/backlog, or segment-margin compression despite revenue growth.

Contrarianly, the apparent value discount may be rational if consensus is embedding an overly smooth transition to higher-quality recurring revenue. GEHC has less immediate exposure to the high-growth obesity-drug and robotics narratives supporting select healthcare equipment names, so a simple valuation comparison can overstate upside. No read-through to NNOX is warranted: its economics, commercialization risk, and valuation drivers are fundamentally different from incumbent imaging vendors.

Key Decisions for Investors

• Maintain GEHC on a 1-3 month earnings watchlist rather than chase the article-driven signal; initiate a long only after management confirms order growth and raises or reiterates full-year margin/FCF guidance. Target 10-15% upside from multiple normalization versus 7-10% downside on a guidance miss.
• For a market-neutral healthcare-equipment expression, consider long GEHC / short PHG over 6-12 months if GEHC demonstrates service/software mix expansion while PHG remains exposed to restructuring and order-cycle risk. Exit if GEHC's organic growth or adjusted EBIT margin underperforms PHG for two consecutive quarters.
• Use the next results as the decision point: require evidence of backlog conversion, service attach-rate improvement, and stable China demand. If any are absent, avoid adding despite favorable headline valuation metrics.
• Do not establish NNOX exposure on this item; set an alert only for independently verified installation, utilization, and cash-burn data, which are required before any competitive-imaging thesis can be evaluated.